

NanoRepro AG

Germany / Medical Technology
 Frankfurt
 Bloomberg: NN6 GR
 ISIN: DE0006577109

Initiation of
 coverage

RATING
PRICE TARGET

Return Potential
 Risk Rating

BUY
€ 2.00

40.4%
 High

UNLOCKING VALUE WITH RAPID DIAGNOSTICS

NanoRepro AG develops, manufactures, and distributes CE-certified rapid diagnostic tests (self-tests) and food supplements for home and professional use. The company has made significant strides over the last year in boosting its operations with new partnerships for distribution and product development. This has resulted in a surge in sales with 2016 turnover growing 242% to €1.5m. We expect the recent performance to receive a boost with a move into retail channels and look for 63% Y/Y top line growth to €3m in 2018. We initiate coverage with a Buy recommendation and a price target of €2.00.

Sizable “Made in Germany” portfolio NanoRepro develops and distributes a line of rapid diagnostics (self-tests) on an international scale. The current portfolio contains 25 point-of-care kits for the consumer and professional marketplaces. Management have forged a partnership with a local specialist for a re-shoring of production allowing NanoRepro to stamp its products with the highly regarded “Made in Germany” brand. Management also hint that the development pipeline could yield six new products for distribution by the end of 2018.

Attractive growth potential in a nascent market Home self-testing is nothing new. Home pregnancy tests are widely accepted globally and appreciated for their first indication reliability. Recent innovations have spawned a variety of new rapid diagnostic products, which allow patients to self-diagnose suspected afflictions. Patients can now test for fertility, allergies and preventative healthcare issues. Tests are administered in the comfort of home without the hassle of having to get to the doctor in today’s stretched health care system.

Primed for strong growth We model a top line CAGR of 46.4% for the period 2017 – 2019. We believe the company has an opportunity to reach the double digit million sales level in the next four years with its product and international expansion roadmap. Given a largely established and scalable operational structure, we believe the increase in revenues will quickly translate into profitability. We expect the company to be EBITDA positive in 2018 on 63% top line growth.

FINANCIAL HISTORY & PROJECTIONS

	2014	2015	2016	2017E	2018E	2019E
Revenue (€m)	0.51	0.45	1.54	1.87	3.06	4.83
Y/Y growth	-50.5%	-12.6%	242.0%	21.8%	63.2%	58.0%
EBITDA (€m)	0.06	-0.96	-0.85	-0.51	0.01	0.79
EBITDA margin	n.a.%	n.a.	n.a.	n.a.	0.3%	16.4%
Net income (€m)	-0.03	-1.18	-0.55	-0.72	-0.21	0.58
EPS (diluted) (€)	-0.01	-0.27	-0.12	-0.12	-0.03	0.09
DPS (€)	0.00	0.00	0.00	0.00	0.00	0.00
FCF (€m)	0.01	-1.32	-1.15	-0.67	-0.23	0.62
Net gearing	48.6%	-9.5%	-12.3%	-31.1%	-26.2%	-37.4%
Liquid assets (€m)	0.00	0.23	0.53	1.34	1.10	1.57

RISKS

Risks include but are not limited to: small size, weak cash position, and untested marketplace.

COMPANY PROFILE

NanoRepro AG develops, manufactures, and distributes CE-certified rapid diagnostic tests (self-tests) and food supplements for home and professional use. The company distributes both into domestic and international markets. NanoRepro has been publicly listed since 2008 and is headquartered in Marburg, Germany.

MARKET DATA

As of 10/16/2017

Closing Price	€ 1.43
Shares outstanding	6.22m
Market Capitalisation	€ 8.86m
52-week Range	€ 0.93 / 2.25
Avg. Volume (12 Months)	17,431

Multiples	2016	2017E	2018E
P/E	n.a.	n.a.	n.a.
EV/Sales	5.6	4.6	2.8
EV/EBITDA	n.a.	n.a.	1068.1
Div. Yield	0.0%	0.0%	0.0%

STOCK OVERVIEW



COMPANY DATA

As of 30 Jun 2017

Liquid Assets	€ 0.48m
Current Assets	€ 1.05m
Intangible Assets	€ 1.88m
Total Assets	€ 3.53m
Current Liabilities	€ 0.23m
Shareholders' Equity	€ 3.27m

SHAREHOLDERS

Management	10.0%
Kuschma Family	8.9%
Free Float	81.1%



INVESTMENT CASE

Restructuring has company primed for exceptional growth

NanoRepro has undertaken a number of initiatives in the past year to boost operations, previously characterised by stagnating growth, and to strongly position itself in the nascent market for rapid diagnostics (self-tests). Management forged a distribution partnership with industry heavyweight Hartmann resulting in a 270% spike in domestic activities, while international operations have also jumped some 190%. The international footprint now covers the DACH region, Spain, England, South Africa, Brazil, and China. We also like the company for its broad portfolio of self-tests and low production costs thanks to re-shoring of production, which is now in the hands of a local partner.

A reliable alternative to “Dr Google” and waiting rooms

Patients are increasingly taking a more active self-diagnostic approach to health care, due to increasing difficulty in getting timely appointments with their trusted physicians. Long waits often send patients to “Dr Google” in search of answers. The information found online is almost always varied, inconclusive and often alarming. Self-tests represent an alternative to make a quick assessment or diagnosis of an indication, thus providing some comfort while waiting for appointments or eliminating the need for a visit all together. Aside from the widely known and accepted home pregnancy test, rapid diagnostics are largely new and innovative with insufficient market data at present to accurately gauge consumer acceptance. However, the market size for home pregnancy tests tops €85m p.a. in Germany alone. We therefore believe people will also increasingly use self-tests as awareness grows, given the higher ratio of patients who suffer from conditions now measurable with rapid diagnostic tests. For instance, one of six couples struggles to get pregnant. Couples can now take initial steps in the comfort of their home to assess fertility issues. We thus believe we are at the very beginning of a major market opportunity for self-diagnostic tests.

Largest portfolio of self-diagnostic tests with Made in Germany branding

NanoRepro AG boasts a portfolio of 25 rapid tests for family planning, health care, allergy and food intolerance, as well as self-tests for professional use (B2B). A line of six food supplements rounds out the product line. This compares favourably to large players, such as Stada AG, which markets only six self diagnostic products. All products have the required CE-Marking allowing for European distribution. NanoRepro is currently developing a number of new self-tests in partnership with its German based R&D partner and plans to bring another six point-of-care diagnostic tests to market by the end of 2018 (table 2). The cooperation also allows the company to use the well regarded “Made in Germany” label, providing European patients with a higher degree of confidence in the products’ quality.

Portfolio expansion and internationalisation drive growth scenario

After years of struggling to reach escape velocity in terms of sales, we believe the company has the building blocks now in place to significantly grow its top line and drive results towards profitability. We look for a revenue CAGR of 46.4% for the period 2017—2019. The Hartmann agreement sparked Y/Y sales growth of 242% in 2016 to €1.5m and 63% in H1/17 to €0.5m, albeit from low volumes. Our confidence in further growth stems from agreements in place, which suggest a high likelihood that the company will get its products onto retail shelves of drugstore and grocery chains. Given NanoRepro’s lean operating structure, the boost in sales should translate into profitability at the EBITDA level next year assuming volumes approach the €3m threshold.

**Current share price undervalues positive outlook**

We use a DCF model to derive the fair value for NanoRepro. Relative metrics are largely unsuitable since NanoRepro will remain unprofitable below the EBITDA level over the near term. We set a price target of €2.00 and initiate coverage with a Buy rating. Our confidence in a sustainable growth scenario stems from management's ability to conclude key partnerships in its home and international markets, tap into emerging health care market trends, and develop a portfolio that positions NanoRepro at the forefront of the nascent self-diagnostics market. In our view, the main risks are: small size, financing needs, market acceptance, and low barriers to entry.



SWOT ANALYSIS

STRENGTHS

- **Large portfolio** NanoRepro boasts the largest portfolio of self-diagnostics in Germany and stamps them "Made in Germany."
- **Strong partners** Locking down a strong distribution and local production partner represents something of a coup for the company that is already paying dividends in terms operational performance.
- **Scalable platform** We believe the company has the infrastructure, sufficient staffing capacity and expertise in place to facilitate the projected growth over the next few years.

WEAKNESSES

- **Profitability** The company has never truly reached escape velocity whereby the top line translates consistently into profitability
- **Small size** Even with the recent and projected growth the company will still have a small market capitalisation and balance sheet.
- **Lack of financial firepower** Limited financial resources handcuff the company's ability to develop its own brand at present and market its own web shop.

OPPORTUNITIES

- **Own brand** With improving operations and sufficient access to capital, NanoRepro could introduce its own line of branded products to boost margins.
- **Internationalisation** "Made in Germany" products are valued abroad as the market for self diagnostics grows. We believe with the right partnerships, the company can be an early mover in the adoption of self-tests.
- **Product innovation** The health care system is constantly looking for ways to curb costs and provide better and faster service to patients. Self-tests represent a chance to help achieve these goals with continued innovation.

THREATS

- **Financing needs** NanoRepro may require further financing rounds to build its own brand and establish mind share in the personal healthcare community.
- **Market acceptance** Self-tests are largely new innovative products with low penetration aside from pregnancy tests. The market could fail to develop as envisioned if consumers fail to embrace the technology.
- **Thin management structure** We appreciate the combined experience of Lisa Jüngst (CEO) and Michael Fuchs (CFO). In our view, the departure of either would likely trigger a setback to the current operational momentum. That said, both executives are under contract through 2019 and have a long term vision for the company.



VALUATION

We use a DCF model to calculate a fair value for NanoRepro. In our view, a peer group is unsuitable for determining a potential value for the company, given the early stage of the company's growth path. According to our estimates, NanoRepro will remain unprofitable over the near term as management unlock new distribution channels in international markets. We expect the company to generate a positive EBITDA in 2018.

We assign a WACC of 13.9% based on our multifactor risk model which takes into account company specific risks such as the strength of management, balance sheet risk and financial risk, the company's competitive position as well as company size and free float. The primary risk in our view is financing and weak balance sheet. We expect the company to raise new capital in the near future and have modelled the placement of up to 622,000 shares with investors by the end of the year. Without a successful cap hike, the company will have limited resources for marketing campaigns required to reach a broad customer base. Our 15% cost of equity estimate is also impacted by the small size of the company in terms of market cap. Forecasting future performance is likewise difficult, given the history of loss making. We have assumed a 2.0% terminal growth rate for sales and estimate a 30% tax rate, given expectations that Germany will remain the core market going forward.

Our model discounts cash flows from 2030 for a total enterprise value of €12.7m, of which 64% stems from the explicit period. We forecast a top-line CAGR of 46.4% for 2017-2019 including 2017 Y/Y growth of 22%. Our DCF valuation produces a post-money fair value of €13.9m adjusted for the net cash position of €0.4m at the end of 2016 plus €0.9m we expect NanoRepro to raise in Q4/17. Based on fully diluted (post-money) shares outstanding of 6.842m, our fair value estimate corresponds to €2.00 / share.

All figures in EUR	2017E	2018E	2019E	2020E	2021E	2022E	2023E	2024E
Sales	1,874,928	3,059,077	4,833,341	7,250,012	9,425,016	10,838,768	11,922,645	12,757,230
NOPLAT	-706,680	-196,932	412,268	1,230,922	1,871,525	2,246,560	2,463,503	2,673,667
+ depreciation & amortisation	194,992	204,958	203,000	72,500	94,250	108,388	119,226	127,572
Net operating cash flow	-511,688	8,026	615,268	1,303,422	1,965,775	2,354,948	2,582,729	2,801,240
- total investments (CAPEX and WC)	-153,052	-241,257	-378,364	-517,628	-479,423	-330,947	-277,685	-222,080
Capital expenditures	-45,561	-12,542	-19,817	-29,725	-38,643	-44,439	-48,883	-52,305
Working capital	-107,491	-228,715	-358,547	-487,903	-440,781	-286,508	-228,802	-169,775
Free cash flows (FCF)	-664,740	-233,231	236,904	785,795	1,486,351	2,024,001	2,305,044	2,579,160
PV of FCF's	-647,406	-199,394	177,786	517,648	859,501	1,027,391	1,027,080	1,008,796

All figures in thousands	
PV of FCFs in explicit period	8,165,690
PV of FCFs in terminal period	4,579,991
Enterprise value (EV)	12,745,681
+ Net cash / - net debt (post money)	1,224,945
+ Investments / minority interests	0
Shareholder value	13,970,626
Fair value per share (€)	2.04

		Terminal growth rate						
		0.5%	1.0%	1.5%	2.0%	2.5%	3.0%	3.5%
WACC	10.9%	2.75	2.81	2.88	2.95	3.04	3.13	3.23
	11.9%	2.44	2.48	2.53	2.58	2.64	2.71	2.78
	12.9%	2.18	2.21	2.25	2.29	2.33	2.38	2.43
	13.9%	1.96	1.98	2.01	2.04	2.07	2.11	2.15
	14.9%	1.77	1.79	1.81	1.84	1.86	1.89	1.92
	15.9%	1.61	1.63	1.65	1.66	1.68	1.70	1.73
	16.9%	1.48	1.49	1.50	1.51	1.53	1.55	1.56
	13.9%	1.48	1.49	1.50	1.51	1.53	1.55	1.56

*Please note our model runs through 2030 and we have only shown the abbreviated version for formatting purposes



COMPANY PROFILE

Founded in 2006 by a group led by Dr Stiller, NanoRepro AG specialises in the development and marketing of CE-certified rapid diagnostic tests (90% of revenue) and food supplements (10% of revenue). Self-tests are sold into the home and professional healthcare channels. Germany accounts for 81% of the sales and the company is making strong inroads into international markets throughout the EU and South Africa.

In 2016, the company employed a staff of 14 at its headquarters in Marburg, Germany. NanoRepro is led by Lisa Jüngst, who was elected to the Executive Board in April 2013. The company floated its shares on the Frankfurt Stock Exchange in 2008 and aims to capitalise on the trends in personal health care, where self-diagnostic products are growing in popularity. In a world, where health management is becoming increasingly difficult and costly to manage, NanoRepro aims to support individuals with a line of simple and effective products. The line of self-tests are appreciated by patients for their ability deliver a speedy and reliable result in a world where health care management is becoming increasingly complex and time consuming. Patients can now benefit from the same quality standards from tests administered at the doctor or hospital, as they take greater responsibility for their health and well being.



PRODUCT PORTFOLIO

NanoRepro currently has a portfolio of 25 rapid diagnostic tests for home use and professional practitioners. The product line comprises solutions for family planning, preventive healthcare, allergies, and infectious diseases. The manufacturer's suggested retail price (MSRP) for items in the product catalogue ranges from €5—€25. All products have CE-Certification for European admission and a PZN (Central Pharmaceutical Number). The company also markets a line of supplements for a variety of indications as shown below.

Table 1: Current product offerings with local production

PRODUCT PORTFOLIO		
FAMILY PLANNING		
OvuQuick (Cassette & Midstream)		Ovulation Test
GraviQuick (Cassette & Midstream)		Pregnancy Test
GraviQuick Early (Cassette & Midstream)		Early Pregnancy Test
MenoQuick		Menopause Test
VagiQuick		Vaginal Yeast Infection Test
FertiQuick		Male Fertility Test
FerritinCheck		Ferritin Concentration Test
TSHCheck		Thyroid Insufficiency Test
PREVENTIVE HEALTHCARE LINE		
FOBCheck		Fecal Occult Blood Test
Heli-C-Check		Helicobacter Pylori Test
Alcohol Test		Alcohol Test
Drug Test		Drug Test
ALLERGY LINE		
GlutenCheck		Gluten Intolerance Test
AllergoCheck		Grass Pollen, Dust Mite, Cat Hair Allergy Test
MilkCheck		Milk Allergy Test
EggCheck		Egg White Protein Allergy Test
TESTS FOR PROFESSIONAL USE		FOOD SUPPLEMENTS
HIV-QUICK	Anti-HIV (1&2) Test	alphabiol Fertility
Troponin I	Cardiac Troponin Test	alphabiol Pregnancy
D-DIMER	D-Dimer Concentration Test	alphabiol Cranberry
Influenza AB	Influenza Type A and B Test	alphabiol Menopause
STREP A	Streptokokki A Test	alphabiol Hair & Skin
Microalbumin	Microalbumin Test	alphabiol Ferritin

Source: First Berlin Equity Research; Company

More products on the way The company has a promising product pipeline and plans to roll out the following products over the coming quarters. The launch dates are only indications and may be subject to delays and financing needs.

Table 2: Development pipeline

Indication	Launch
TSH Test (Thyroid deficiency)	Q4/17
CRP Test (Infection Indicator)	Q1/18
Rheumatism Test	Q2/18
Cholesterol Test	Q3/18
Calprotectin (Intestinal infection)	Q4/18
Heart Attack Marker	Q4/18
Serotonin Test (Depression)	Q1/19

Source: First Berlin Equity Research; Company



FINANCIAL FORECASTS—STRONG GROWTH AHEAD

Sales segmentation is divided into domestic and international channels. At home, NanoRepro handles some marketing activities for the brands "QUICK" and "CHECK." Moreover, OEM partners purchase products from NanoRepro to sell and market under their own brand. In this case, the OEM assumes approval responsibilities and promotional and activities. International sales are orchestrated by a distribution partner, who also assumes the associated approval and marketing duties and costs. Sales from NanoRepro's online shop, ZuhauseTEST (zuhausestest.de), and Amazon (AMZN US) make up only a fraction of our forecasts until we see an improved track record. Presently, wholesale makes up the lion's share of revenues, but we look for the company to make a strong move into the retail channel in the near future.

Table 3: Six month 2017 profit and loss KPIs


All figures in EUR	H1/17	H1/16	% delta
Revenue	855,333	524,774	63.0%
Gross profit	466,225	437,392	6.6%
Margin (% on revenues)	37.3%	37.8%	-
EBITDA	-261,026	-371,677	-29.8%
Margin (% on revenues)	-30.5%	-70.8%	-
Net income	-382,025	-479,911	-20.4%

Source: First Berlin Equity Research; Company

Six month reporting showed a sharp increase in sales of 63% albeit from a very low base of €524k. EBITDA improved to €-261k (H1/16: €-372k). We expect to see continued signs that business is improving, thanks to the Hartmann partnership and a move into retail. We model a three year sales CAGR of 46.4% for the period 2017—2019, driven predominantly by self-test revenue streams. We look for sales to top the €3m mark in 2018.

We model a gross margin (GM) of 45% for the company with the expected sales mix of the aforementioned channels. ZuhauseTEST offers the largest GM uplift potential. However, the contribution is still too small to significantly impact the metric. The recent upswing is traced to the new production partnerships. Not only has the reshoring of production resulted in a "Made in Germany" product line, it has also cut costs.

Figure 1: Revenue and gross margin development



Source: First Berlin Equity Research; Company




The staff headcount is 14 giving the company a lean operating structure capable of orchestrating the pending growth with no required additions. Personnel expenses consumed some 43% of sales in 2016. We expect this ratio fall to below 18% in 2019 and trend even lower due to scalability and low staffing needs.

Other OpEx mainly encompasses SG&A. We note that distribution partners shoulder the bulk of outward marketing costs, thus the line item reflects standard operational costs. Initial research for product development occurs in house, while the production partner assumes production and testing. We also see great potential to improve on the 65% other OpEx / sales ratio realised last year. We target 15.7% by 2019. We expect the other OpEx line to also decrease Y/Y, given the one-off costs incurred last year in conjunction with a build-up in operations and securing new partners. The combined scale effects should allow the company to produce a positive result at the EBITDA level in 2018, if the expected spike in retail sales actually materialises.

We expect depreciation and amortisation to remain around €200k per annum over the next few years as the company writes down capitalised legacy costs. We therefore expect EBIT to remain negative until 2019. Given our expectation that financing needs will be chiefly met with equity financing rounds, our model contains only marginal interest costs. Loss carry forwards will also keep tax expenses low over the mid term.

Figure 2: EBITDA development



Source: First Berlin Equity Research; Company



Capital increase in the works to shore up the balance sheet and finance growth The balance sheet is characterised by sizable working capital (WC) and intangible asset positions. The latter contains capitalised product approval expenses for previous activities in Russia. We expect these to be fully amortised over a five year period.


Table 4: Six month 2017 financial highlights

All figures in EUR	H1/17	2016	Delta
Cash	476,940	530,121	-10.0%
Financial debt (short- and long-term)	155,976	155,976	0.0%
Net debt	-320,964	-374,145	-14.2%
Total assets	3,530,102	3,513,398	0.5%
Shareholders' equity	3,274,125	3,034,620	7.9%
Equity ratio	92.7%	86.4%	-

Source: First Berlin Equity Research; Company

NanoRepro is working on curbing working capital consumption and has been writing down obsolete inventories since Mr Fuchs took over the financing helm a year ago. With stricter discipline, we believe the company will be able to keep inventory days at two months. We also expect receivables to remain below two months going forward with the future sales mix, while payables will range between 20 – 30 days. We thus expect the company to run at a WC/Sales ratio of some 20% going forward.

Figure 3: Working capital development



Source: First Berlin Equity Research; Company

NanoRepro has a one year revolver (H1/17: €155k) on the balance sheet, which we believe represents the peak debt load assuming near term equity capital raises. We model the issuance of up to 622,000 new shares (10% of share capital) by the end of this year. We have assumed a successful placement at €1.40 / share—a 2% discount to the current share price. This should give the company sufficient funds to move into planned distribution abroad and cover the associated working capital needs. We have not assumed development of branded products in our model at this stage. This would require additional financing rounds.

We expect net operating cash flow to remain negative through the end of next year (2018E: €-193k), owing mainly to working capital consumption. The rise in sales should translate into adequate profitability to yield positive net operating cash flow the following year. Given low CapEx intensity, we expect this to convert into positive free cash flows (FCF) in 2019. We expect the company to offset negative FCF with the aforementioned cap hike.



MANAGEMENT

CEO

Lisa Jüngst has been with NanoRepro since 2006 and was named to the executive team in April 2013. Her company roots are in marketing, finance, personnel, and investor relations, giving her first hand insight into operations. Today, she cultivates relationships with key partners and customers and spearheads internationalisation. Ms Jüngst studied Business Management at the University of Fulda and is a founding member of PaediProtect AG. She is also a member of the Young Entrepreneurs Alliance.

CFO

Michael Fuchs joined NanoRepro in September 2016 as CFO and recently extended his contact by two years. Mr Fuchs has 25 years experience working in the financial sector including a stint at Generali Group, where he had a senior position. He studied Business Administration at the University of Cologne with a focus on finance and taxation.

Supervisory Board Chairman

Dr Olaf Stiller brings seven years experience at NanoRepro having previously served as Managing Director and CEO. He helped guide NanoRepro and Formycon AG from start-up to public listing and continues to serve as Supervisory Board Chairman of Formycon. Dr Stiller obtained his doctorate with the scholarship for talented individuals from the Federal Ministry of Education and Research.

Deputy Chairman of Supervisory Board

Michael Tillmann is CEO of Vela Holding Pte. Ltd. Singapore and supports NanoRepro with strategic planning. Previously, Mr Tillmann was CEO at Roche Diagnostics. He has over 20 years of experience in top management positions at international companies.

Supervisory Board Member

Dr Michael Kern serves as Supervisory Board Chairman of SPORTTOTAL AG. Among his previous posts, he was responsible for the marketing and after sales divisions at Volkswagen, served as Chairman of the Management Board of A.T.U., and as Chairman and Chief Executive Officer at Kamps AG. He also held a number of senior positions at Kaufhof Group. Dr Kern holds a doctorate in economics and is a graduate of the Bergische Universität Wuppertal.

Supervisory Board Member

Dr Bhunesh Agrawal combines over 40 years of industry experience and academic credentials across a number of corporate positions. At the start of his career, he spent 15 years at the Free University of Berlin in research, teaching and in patient management. Dr Agrawal is a medical doctor by training specialised in internal medicine, clinical pharmacology, pharmacology and toxicology in Germany. He received his MBA from the Open University, UK and his PhD from the Free University of Berlin.



SHAREHOLDERS & STOCK INFORMATION

Stock Information	
ISIN	DE0006577109
WKN	657 710
Bloomberg ticker	NN6 GR
No. of issued shares	6,220,000
Transparency Standard	Entry Standard
Country	Germany
Sector	Med -Tech
Subsector	Health care

Source: Börse Frankfurt, First Berlin Equity Research

Shareholder Structure	
Management	10.0%
Kuschma Family	8.9%
Free Float	81.1%

Source: NanoRepro AG



INCOME STATEMENT

All figures in EUR	2015	2016	2017E	2018E	2019E
Revenues	450,116	1,539,295	1,874,928	3,059,077	4,833,341
Capitalised own work	174,891	281,833	243,480	192,000	192,000
Total output	625,007	1,821,128	2,118,408	3,251,077	5,025,341
Cost of goods sold	-284,126	-1,022,131	-1,163,638	-1,687,999	-2,639,004
Gross profit	340,881	798,997	954,770	1,563,078	2,386,337
Personnel expenses	-496,354	-657,836	-773,343	-824,944	-840,854
Other OpEx	-885,585	-1,003,373	-712,605	-739,285	-760,456
Other income	82,499	8,935	19,490	9,177	6,928
EBITDA	-958,559	-853,277	-511,688	8,026	791,954
Depreciation & amortisation	-216,769	-250,760	-194,992	-204,958	-203,000
Operating income (EBIT)	-1,175,328	-1,104,037	-706,680	-196,932	588,954
Net financial result	-427	-4,332	-9,358	-7,750	-3,875
Pre-tax income (EBT)	-1,175,755	-1,108,369	-716,039	-204,682	585,079
Income taxes	-101	556,692	-838	-472	-5,851
Net income / loss	-1,175,855	-551,677	-716,876	-205,154	579,228
Diluted EPS (in €)	-0.27	-0.12	-0.12	-0.03	0.09
Ratios					
Gross margin on revenues	36.9%	33.6%	37.9%	44.8%	45.4%
EBITDA margin on revenues	-213.0%	-55.4%	-27.3%	0.3%	16.4%
EBIT margin on revenues	-261.1%	-71.7%	-37.7%	-6.4%	12.2%
Net margin on revenues	-261.2%	-35.8%	-38.2%	-6.7%	12.0%
Tax rate	0.0%	50.2%	-0.1%	-0.2%	-1.0%
Expenses as % of revenues					
Personnel expenses	-110.3%	-42.7%	-41.2%	-27.0%	-17.4%
Other OpEx	-196.7%	-65.2%	-38.0%	-24.2%	-15.7%
Depreciation & amortisation	-48.2%	-16.3%	-10.4%	-6.7%	-4.2%
Y-Y Growth					
Revenues	-12.6%	242.0%	21.8%	63.2%	58.0%
Operating income	n.m.	n.m.	n.m.	n.m.	n.m.
Net income/ loss	n.m.	n.m.	n.m.	n.m.	n.m.



BALANCE SHEET

All figures in EUR	2015	2016	2017E	2018E	2019E
Assets					
Current assets, total	797,742	1,143,150	1,875,555	1,900,288	2,789,451
Cash and equivalents	230,506	530,121	1,340,383	1,100,426	1,565,842
Trade receivables	35,832	31,064	282,523	460,957	728,312
Inventories	403,260	422,780	191,283	277,479	433,809
Other ST assets	128,144	159,185	61,365	61,426	61,488
Non-current assets, total	1,641,059	2,370,248	2,220,816	2,028,400	1,630,228
Property, plant & equipment	20,507	13,302	13,864	14,170	14,654
Goodwill & other intangibles	1,595,552	1,774,946	1,624,952	1,432,230	1,248,563
Financial assets	25,000	25,000	25,000	25,000	25,000
Deferred taxes	0	557,000	557,000	557,000	342,011
Total assets	2,438,801	3,513,398	4,096,371	3,928,689	4,419,679
Shareholders' equity & debt					
Current liabilities, total	106,119	353,911	260,885	297,086	207,514
Trade payables	73,592	167,230	79,701	115,616	180,754
ST debt	13,451	155,976	155,000	155,000	0
Other ST financial liabilities	0	12,988	8,201	8,217	8,234
Other current liabilities	19,076	17,717	17,983	18,252	18,526
Long-term liabilities, total	58,500	124,867	25,411	26,682	28,016
LT provisions	58,500	124,867	25,411	26,682	28,016
Shareholders' equity	2,274,182	3,034,620	3,810,075	3,604,921	4,184,149
Total consolidated equity and debt	2,438,801	3,513,398	4,096,371	3,928,689	4,419,679
Ratios					
Current ratio (x)	7.5	3.2	7.2	6.4	13.4
Quick ratio (x)	3.7	2.0	6.5	5.5	11.4
Net debt	-217,055	-374,145	-1,185,383	-945,426	-1,565,842
Net gearing	-10%	-12%	-31%	-26%	-37%
Return on equity (ROE)	-51.7%	-18.2%	-18.8%	-5.7%	13.8%
Capital employed (CE)	1,981,559	2,074,862	2,032,921	2,069,220	2,244,584
Return on capital employed (ROCE)	-59%	-53%	-35%	-10%	26%



CASH FLOW STATEMENT

All figures in EUR	2015	2016	2017E	2018E	2019E
Pre-tax income	-1,175,855	-551,677	-716,039	-204,682	585,079
Depreciation and amortisation	216,769	208,808	194,992	204,958	203,000
Change in trade rec & other assets	17,359	-45,800	77,858	-264,691	-208,757
Change in payable & other liabilities	7,000	171,700	-191,506	37,472	66,762
Operating cash flow	-934,727	-216,969	-634,695	-226,944	646,084
Interest expense paid	427	4,332	9,360	7,750	3,875
Tax paid	-300	-556,456	-838	-472	-5,851
Net operating cash flow	-934,600	-769,093	-626,172	-219,665	644,108
CapEx	-390,013	-380,994	-45,561	-12,542	-19,817
Cash flow from investing	-390,013	-380,994	-45,561	-12,542	-19,817
Free cash flow (FCF)	-1,324,613	-1,150,087	-671,732	-232,207	624,292
Equity inflow, net	1,542,900	1,312,115	1,492,331	0	0
Debt inflow, net	-107,500	142,500	-976	0	-155,000
Interest paid	0	-4,913	-9,360	-7,750	-3,875
Cash flow from financing	1,435,400	1,449,702	1,481,995	-7,750	-158,875
Net cash flows	110,787	299,615	810,262	-239,957	465,417
Cash, start of the year	119,720	230,506	530,121	1,340,383	1,100,426
Cash, end of the year	230,506	530,121	1,340,383	1,100,426	1,565,842
EBITDA/share (in €)	0.00	-0.18	-0.08	0.00	0.12
Y-Y Growth					
Operating cash flow	n.m.	n.m.	n.m.	n.m.	n.m.
Free cash flow	n.m.	n.m.	n.m.	n.m.	n.m.
EBITDA/share	n.m.	n.m.	n.m.	n.m.	9767.7%

FIRST BERLIN RECOMMENDATION & PRICE TARGET HISTORY

Report No.:	Date of publication	Previous day closing price	Recommendation	Price target
Initial Report	17 October 2017	€ 1.43	Buy	€ 2.00

Authored by: Ellis Acklin, Analyst

Company responsible for preparation:

First Berlin Equity Research GmbH
 Mohrenstraße 34
 10117 Berlin

Tel. 030 80939690 Fax +49 (0)30 - 80 93 96 87

info@firstberlin.com
 www.firstberlin.com

Person responsible for forwarding or distributing this financial analysis: Martin Bailey

Copyright© 2017 First Berlin Equity Research GmbH No part of this financial analysis may be copied, photocopied, duplicated or distributed in any form or media whatsoever without prior written permission from First Berlin Equity Research GmbH. First Berlin Equity Research GmbH shall be identified as the source in the case of quotations. Further information is available on request.

INFORMATION PURSUANT TO SECTION 34B OF THE GERMAN SECURITIES TRADING ACT [WPHG], TO REGULATION (EU) NO 596/2014 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL OF APRIL 16, 2014, ON MARKET ABUSE (MARKET ABUSE REGULATION) AND TO THE GERMAN ORDINANCE ON THE ANALYSIS OF FINANCIAL INSTRUMENTS [FINANV]

First Berlin Equity Research GmbH (hereinafter referred to as: "First Berlin") prepares financial analyses while taking the relevant regulatory provisions, in particular the German Securities Trading Act [WpHG], Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014, on market abuse (market abuse regulation) and the German Ordinance on the Analysis of Financial Instruments [FinAnV] into consideration. In the following First Berlin provides investors with information about the statutory provisions that are to be observed in the preparation of financial analyses.

CONFLICTS OF INTEREST

In accordance with Section 34b Paragraph 1 of the German Securities Trading Act [WpHG] and Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014, on market abuse (market abuse regulation) financial analyses may only be passed on or publicly distributed if circumstances or relations which may cause conflicts of interest among the authors, the legal entities responsible for such preparation or companies associated with them are disclosed along with the financial analysis.

First Berlin offers a range of services that go beyond the preparation of financial analyses. Although First Berlin strives to avoid conflicts of interest wherever possible, First Berlin may maintain the following relations with the analysed company, which in particular may constitute a potential conflict of interest (further information and data may be provided on request):

- The author, First Berlin, or a company associated with First Berlin holds an interest of more than five percent in the share capital of the analysed company;
- The author, First Berlin, or a company associated with First Berlin provided investment banking or consulting services for the analysed company within the past twelve months for which remuneration was or was to be paid;
- The author, First Berlin, or a company associated with First Berlin reached an agreement with the analysed company for preparation of a financial analysis for which remuneration is owed;
- The author, First Berlin, or a company associated with First Berlin has other significant financial interests in the analysed company;

In order to avoid and, if necessary, manage possible conflicts of interest both the author of the financial analysis and First Berlin shall be obliged to neither hold nor in any way trade the securities of the company analyzed. The remuneration of the author of the financial analysis stands in no direct or indirect connection with the recommendations or opinions represented in the financial analysis. Furthermore, the remuneration of the author of the financial analysis is neither coupled directly to financial transactions nor to stock exchange trading volume or asset management fees.

If despite these measures one or more of the aforementioned conflicts of interest cannot be avoided on the part of the author or First Berlin, then reference shall be made to such conflict of interest.

PRICE TARGET DATES

Unless otherwise indicated, current prices refer to the closing prices of the previous trading day.

AGREEMENT WITH THE ANALYSED COMPANY AND MAINTENANCE OF OBJECTIVITY

The present financial analysis is based on the author's own knowledge and research. The author prepared this study without any direct or indirect influence exerted on the part of the analysed company. Parts of the financial analysis were possibly provided to the analysed company prior to publication in order to avoid inaccuracies in the representation of facts. However, no substantial changes were made at the request of the analysed company following any such provision.

ASSET VALUATION SYSTEM

First Berlin's system for asset valuation is divided into an asset recommendation and a risk assessment.

ASSET RECOMMENDATION

The recommendations determined in accordance with the share price trend anticipated by First Berlin in the respectively indicated investment period are as follows:

STRONG BUY: An expected favourable price trend of more than 50% combined with sizeable confidence in the quality and forecast security of management.

BUY: An expected favourable price trend of more than 25% percent.

ADD: An expected favourable price trend of between 0% and 25%.

REDUCE: An expected negative price trend of between 0% and -15%.

SELL: An expected negative price trend of more than -15%.

RISK ASSESSMENT

The First Berlin categories for risk assessment are low, average, high and speculative. They are determined by ten factors: Corporate governance, quality of earnings, management strength, balance sheet and financial risk, competitive position, standard of financial disclosure, regulatory and political uncertainty, strength of brandname, market capitalisation and free float. These risk factors are incorporated into the First Berlin valuation models and are thus included in the target prices. First Berlin customers may request the models.

INVESTMENT HORIZON

Unless otherwise stated in the financial analysis, the ratings refer to an investment period of twelve months.

UPDATES

At the time of publication of this financial analysis it is not certain whether, when and on what occasion an update will be provided. In general First Berlin strives to review the financial analysis for its topicality and, if required, to update it in a very timely manner in connection with the reporting obligations of the analysed company or on the occasion of ad hoc notifications.

SUBJECT TO CHANGE

The opinions contained in the financial analysis reflect the assessment of the author on the day of publication of the financial analysis. The author of the financial analysis reserves the right to change such opinion without prior notification.

Legally required information regarding

- key sources of information in the preparation of this research report
- valuation methods and principles
- sensitivity of valuation parameters

can be accessed through the following internet link: <http://firstberlin.com/disclaimer-english-link/>

SUPERVISORY AUTHORITY: Bundesanstalt für Finanzdienstleistungsaufsicht (German Federal Financial Supervisory Authority) [BaFin], Graurheindorferstraße 108, 53117 Bonn and Lurgiallee 12, 60439 Frankfurt

EXCLUSION OF LIABILITY (DISCLAIMER)

RELIABILITY OF INFORMATION AND SOURCES OF INFORMATION

The information contained in this study is based on sources considered by the author to be reliable. Comprehensive verification of the accuracy and completeness of information and the reliability of sources of information has neither been carried out by the author nor by First Berlin. As a result no warranty of any kind whatsoever shall be assumed for the accuracy and completeness of information and the reliability of sources of information, and neither the author nor First Berlin, nor the person responsible for passing on or distributing the financial analysis shall be liable for any direct or indirect damage incurred through reliance on the accuracy and completeness of information and the reliability of sources of information.

RELIABILITY OF ESTIMATES AND FORECASTS

The author of the financial analysis made estimates and forecasts to the best of the author's knowledge. These estimates and forecasts reflect the author's personal opinion and judgement. The premises for estimates and forecasts as well as the author's perspective on such premises are subject to constant change. Expectations with regard to the future performance of a financial instrument are the result of a measurement at a single point in time and may change at any time. The result of a financial analysis always describes only one possible future development – the one that is most probable from the perspective of the author – of a number of possible future developments.

Any and all market values or target prices indicated for the company analysed in this financial analysis may not be achieved due to various risk factors, including but not limited to market volatility, sector volatility, the actions of the analysed company, economic climate, failure to achieve earnings and/or sales forecasts, unavailability of complete and precise information and/or a subsequently occurring event which affects the underlying assumptions of the author and/or other sources on which the author relies in this document. Past performance is not an indicator of future results; past values cannot be carried over into the future.

Consequently, no warranty of any kind whatsoever shall be assumed for the accuracy of estimates and forecasts, and neither the author nor First Berlin, nor the person responsible for passing on or distributing the financial analysis shall be liable for any direct or indirect damage incurred through reliance on the correctness of estimates and forecasts.

INFORMATION PURPOSES, NO RECOMMENDATION, SOLICITATION, NO OFFER FOR THE PURCHASE OF SECURITIES

The present financial analysis serves information purposes. It is intended to support institutional investors in making their own investment decisions; however in no way provide the investor with investment advice. Neither the author, nor First Berlin, nor the person responsible for passing on or distributing the financial analysis shall be considered to be acting as an investment advisor or portfolio manager vis-à-vis an investor. Each investor must form his own independent opinion with regard to the suitability of an investment in view of his own investment objectives, experience, tax situation, financial position and other circumstances.

The financial analysis does not represent a recommendation or solicitation and is not an offer for the purchase of the security specified in this financial analysis. Consequently, neither the author nor First Berlin, nor the person responsible for passing on or distributing the financial analysis shall as a result be liable for losses incurred through direct or indirect employment or use of any kind whatsoever of information or statements arising out of this financial analysis.

A decision concerning an investment in securities should take place on the basis of independent investment analyses and procedures as well as other studies including, but not limited to, information memoranda, sales or issuing prospectuses and not on the basis of this document.

NO ESTABLISHMENT OF CONTRACTUAL OBLIGATIONS

By taking note of this financial analysis the recipient neither becomes a customer of First Berlin, nor does First Berlin incur any contractual, quasi-contractual or pre-contractual obligations and/or responsibilities toward the recipient. In particular no information contract shall be established between First Berlin and the recipient of this information.

NO OBLIGATION TO UPDATE

First Berlin, the author and/or the person responsible for passing on or distributing the financial analysis shall not be obliged to update the financial analysis. Investors must keep themselves informed about the current course of business and any changes in the current course of business of the analysed company.

DUPLICATION

Dispatch or duplication of this document is not permitted without the prior written consent of First Berlin.

SEVERABILITY

Should any provision of this disclaimer prove to be illegal, invalid or unenforceable under the respectively applicable law, then such provision shall be treated as if it were not an integral component of this disclaimer; in no way shall it affect the legality, validity or enforceability of the remaining provisions.

APPLICABLE LAW, PLACE OF JURISDICTION

The preparation of this financial analysis shall be subject to the law obtaining in the Federal Republic of Germany. The place of jurisdiction for any disputes shall be Berlin (Germany).

NOTICE OF DISCLAIMER

By taking note of this financial analysis the recipient confirms the binding nature of the above explanations.

By using this document or relying on it in any manner whatsoever the recipient accepts the above restrictions as binding for the recipient.

QUALIFIED INSTITUTIONAL INVESTORS

First Berlin financial analyses are intended exclusively for qualified institutional investors.

This report is not intended for distribution in the USA, Canada and/or the United Kingdom (Great Britain).